pharmaceutical investing Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
pharmaceutical investing Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
pharmaceutical investing Johnson & Johnson's RYBREVANT FASPRO receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
pharmaceutical investing Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
pharmaceutical investing Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
pharmaceutical investing Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
pharmaceutical investing Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA Robotic Surgical System
pharmaceutical investing Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
pharmaceutical investing Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
pharmaceutical investing Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
pharmaceutical investing Johnson & Johnson presents new IMAAVY® data at European Academy of Neurology 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
